Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNEU-AGE
2018-004316-22Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2019
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pneumococcal disease comparing V114 with Prevnar 13 (2 arms). Primary endpoints: Percentage of participants with a solicited injection-site adverse event, Proportion of participants with adverse events and 1 more. Started Jun 2019; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccinePrevnar 13
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2018-004316-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004316-22.